Cytokinetics was founded in 1998 by pioneers in the field of muscle biology. Over the years, our company has developed an unparalleled expertise, keeping it at the forefront of drug discovery and development for diseases impacting muscle performance. Muscle plays a critical role in everyday physical functionality, including proper circulation, movement, and even the ability to breathe. As a result, conditions or syndromes that lead to dysfunction of muscle have serious consequences on survival and well-being.
Cytokinetics takes a purpose-driven approach by leveraging our unique muscle biology expertise to engineer compounds with specific characteristics aimed at treating diseases that impact muscle function. By directly targeting the sarcomere, the foundation of muscle contraction, the treatments we are developing have the potential to preserve and extend independence and self-reliance in people suffering from debilitating diseases. Cytokinetics is dedicated to helping underserved patient populations which lack effective therapies.
Enrolling by invitationCY 6022 is an Open Label Study to Collect Long-term Safety and Tolerability Data for Aficamten (CK-3773274)
RecruitingA Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS...
RecruitingCY 6031 Study Will Evaluate the Effects of Treatment With Aficamten (CK-3773274) Over a 24-week Period on Card...
RecruitingA Phase 3, Open-Label Extension of COURAGE-ALS (CY 5031)
Clinical Characteristics and Healthcare Resource Utilization among Patients with Obstructive Hypertrophic Cardiomyopathy Treated i...
A Phase 1 Dose-Escalation Study of the Cardiac Myosin Inhibitor Aficamten in Healthy Participants
Effects of omecamtiv mecarbil in heart failure with reduced ejection fraction according to blood pressure: the GALACTIC-HF trial
Effects of Aficamten on cardiac contractility in a feline translational model of hypertrophic cardiomyopathy
Titin-truncating variants in hiPSC cardiomyocytes induce pathogenic proteinopathy and sarcomere defects with preserved core contra...
0 Comments on CYTK stock